Relapse and Treatment Adherence in Patients with Schizophrenia Switching from Paliperidone Palmitate Once-Monthly to Three-Monthly Formulation: A Retrospective Health Claims Database Analysis
Gang Li,Alexander Keenan,Mehmet Daskiran,Maju Mathews,Isaac Nuamah,Camille Orman,Kruti Joshi,Arun Singh,Annabelle Godet,Katalin Pungor,Srihari Gopal
DOI: https://doi.org/10.2147/PPA.S322880
2021-10-03
Patient Preference and Adherence
Abstract:Gang Li, 1 Alexander Keenan, 2 Mehmet Daskiran, 1 Maju Mathews, 3 Isaac Nuamah, 3 Camille Orman, 3 Kruti Joshi, 4 Arun Singh, 3 Annabelle Godet, 5 Katalin Pungor, 6 Srihari Gopal 3 1 Janssen Research & Development, LLC, Raritan, NJ, USA; 2 Janssen Research & Development, LLC, Pennington, NJ, USA; 3 Janssen Research & Development, LLC, Titusville, NJ, USA; 4 Janssen Pharmaceuticals, Titusville, NJ, USA; 5 Janssen-Cilag France, Issy-les-Moulineaux, Ile-de-France, France; 6 Janssen-Cilag Germany, Neuss, North Rhine-Westphalia, Germany Correspondence: Gang Li Eisai Inc., 4 Heitz Lane, Hillsborough, NJ, 08844, USA Tel +1 908 566-2730 Email Purpose: Relapse and treatment adherence to paliperidone palmitate once-monthly (PP1M) and three-monthly (PP3M) formulations in patients with schizophrenia were evaluated and compared using health claims data. Patients and Methods: Data (June 2015&boxhJune 2018) obtained from the MarketScan ® Multi-State Medicaid Database were retrospectively analyzed. Patients aged ≥ 18 years with ≥ 1 claim for schizophrenia diagnosis prior to and/or at index date (i.e., date of first PP3M prescription record for PP3M patients and same month/year as the matched PP3M patients for PP1M patients) and continuous enrollment in the insurance plan for ≥ 12 months prior to index date (baseline) were included. PP1M cohort included patients who received ≥ 4 PP1M doses. PP3M patients were matched with PP1M patients (1:3) using propensity score matching and prevalent new user design. Outcome measures were relapse rate, time to relapse, proportion of days covered (PDC), and level of treatment adherence defined by PDC in five levels. Time to relapse was compared by Kaplan–Meier survival curves and log-rank test with the hazard ratio calculated using Cox proportion hazards model; PDC by t -test, and relapse rate and PDC categories by chi-square test. Results: A total of 1564 patients (428 PP3M and 1136 PP1M) were included. Relapse rate was lower in PP3M cohort (10.5%) compared with PP1M cohort (15.7%). Incidence rate of relapse was 8.98/100 person-years (PY) in PP3M cohort and 13.81/100 PY in PP1M cohort. After a mean (SD) follow-up of 456.1 (240.28) days in PP3M cohort and 465.4 (237.95) days in PP1M cohort, PP3M patients had a significantly lower relapse risk (hazard ratio: 0.65, 95% CI: 0.47, 0.90) than PP1M patients. Treatment adherence was significantly (p< 0.0001) higher in PP3M versus PP1M cohort. Conclusion: Risk of relapse was significantly lower, and treatment adherence was significantly higher in PP3M cohort compared with PP1M cohort. Higher treatment adherence was associated with lower relapse rate. Keywords: health claims, paliperidone palmitate, relapse rate, schizophrenia, three-monthly, treatment adherence Schizophrenia is a chronic condition characterized by hallucinations, delusions, and impaired cognition and perception. Estimates of schizophrenia prevalence in the United States Medicaid population range from 2.16% to 4.01%. 1 Most patients with schizophrenia experience frequent symptomatic exacerbations and relapse, triggered most often by treatment non-adherence or treatment discontinuation. 2,3 Illness relapse is associated with an increased risk of serious, negative outcomes, such as increased overall mortality, violence, damaged relationships, increased stigmatization, disruptions in employment and education, decreased brain volume, treatment resistance, worsening of baseline level of functioning, and increased individual and societal economic burdens. 3–7 Treatment with antipsychotic medications, compared to no treatment, in patients with schizophrenia - a cohort known to suffer from excess mortality compared to the general population - is also associated with a reduced risk of death. 3,8 Relapse prevention is therefore the main goal of schizophrenia management. 9 Nonadherence to antipsychotic therapy is a prominent driver of healthcare resource utilization (HRU) among patients with schizophrenia. Approximately 40%–60% of patients with schizophrenia are partially or totally nonadherent to antipsychotic therapy; 10 with some estimates being as high as 89%. 11 Indeed, even medication gaps of 1 to 10 continuous days is associated with a two-fold increase in risk of hospitalization. 12 This increase in risk adds on to the annual economic burden of schizophrenia in the United States, which was estimated to be USD 155.7 billion in 2013, with a direct healthcare cost of USD 38 billion. Moreover, societal cost -Abstract Truncated-
medicine, general & internal